Program
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978
Its studies are mostly in Lupus Erythematosus, Systemic · Lymphoma, Non-Hodgkin · Arthritis, Rheumatoid · Sjogren's Syndrome, led by Cullinan Therapeutics.
Drug pageAnti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 1, since May 5, 20234 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cullinan Therapeutics | 43 open or running | phase 1since May 5, 2023 | May 5, 2023 | Dec 2026phase 1 · NCT06613360 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 5, 2023First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT05879744 · 3 enrolled · United States
- Sep 20, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06613360 · 24 planned · United States, Australia, Bulgaria and more
- May 20, 2025Phase 1 study in Arthritis, RheumatoidNCT06994143 · 37 planned · Germany, Italy
- Jun 18, 2025Phase 1 study in Sjogren's SyndromeNCT07041099 · 36 planned · United States, France, Germany and more
Ahead
- Dec 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT06613360
- Dec 30, 2027Primary completion: phase 1 study in Arthritis, RheumatoidNCT06994143
- Mar 15, 2028Primary completion: phase 1 study in Sjogren's SyndromeNCT07041099
TargetBeta
“A half-life extended T-cell engaging bispecific antibody comprised of a single chain variable fragment (scFv) targeting the tumor-associated antigen (TAA) CD19, a scFv targeting the T-cell surface antigen CD3, and a single-domain heavy chain variable domain (VHH)-based antibody specific for human se”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| YK012rule | excyte-biopharma-ltd | phase 2 | 5 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rule | cytocares-inc | phase 1 | 4 |
| Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565 | Novartis | phase 1 | 3 |
| ATG-201rule | antengene-biologics-limited | phase 1 | 1 |
| KT501rule | kali-therapeutics-inc | phase 1 | 1 |
| KT502rule | kali-therapeutics-inc | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07041099Sjogren's Syndrome · United States, France, Germany and more | 1 | Recruiting | Mar 15, 2028 | 36 |
| NCT06994143Arthritis, Rheumatoid · Germany, Italy | 1 | Recruiting | Dec 30, 2027 | 37 |
| NCT06613360Lupus Erythematosus, Systemic · United States, Australia, Bulgaria and more | 1 | Recruiting | Dec 2026 | 24 |
| NCT05879744Lymphoma, Non-Hodgkin · United States | 1 | Terminated | Jun 1, 2024 | 3 |
How it is read
Names in the registry
- “CLN-978”, 4 entries
Conditions, from the studies’ own filings
- Lupus Erythematosus, Systemic, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Arthritis, Rheumatoid, 1 study
- Sjogren's Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.